The Latest Breaking News from Sanofi

The Paris Olympics have been a showcase not only for athletic prowess but also for therapies such as ice baths and osteopathy which have little scientifically proven medical value, according to experts.

The biotech industry is experiencing rapid growth owing to new drug innovations and advancements in healthcare. To capitalize on the industry's expansion, it could be wise to invest in solid biotech stocks, Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and Gilead Sciences (GILD), which have revolutionary pipelines. Read on….

Today we meet with British CEO Paul Hudson to find out how he plans to build the Sanofi of tomorrow.

There hasn't been a new COPD treatment in years. But Regeneron stock analysts are closely watching a pair of key FDA decisions.

Regeneron stock joined the 1,000-club this month as enthusiasm grows for its blockbuster drug, Dupixent, in COPD treatment.

Moderna said Monday its Covid/flu vaccine topped rivals from GSK and Sanofi, and its own Spikevax shot. But Moderna stock fell.

Usher will join French pharma giant Sanofi in Washington, D.C., to discuss the importance of early screening for type 1 diabetes.

Sanofi CEO Paul Hudson thinks AI offers 'insane' potential for the pharmaceutical industry, which can spend up to $4 billion developing a drug.

French pharmaceutical company Sanofi announced Tuesday a partnership with ChatGPT-founder OpenAI and US biotech firm Formation Bio to accelerate the use of artificial intelligence in developing drugs.